"I’ve followed uBiome’s trajectory over the years, and have been delighted to see their efforts in democratizing microbiome science and more recently, their leadership in driving the adoption of microbiome-based diagnostics in the clinic.” - Dr. Oh, PhD
SAN FRANCISCO (PRWEB) January 24, 2019
uBiome, the leader in microbial genomics, announces the addition of Dr. Julia Oh, PhD, Assistant Professor of Microbiology at the Jackson Laboratory (JAX), to its Scientific Advisory Board. Joining the board of leading scientists and doctors from around the world, Dr. Oh will bring to uBiome expertise in skin microbial interactions and probiotic treatments for skin and infectious diseases. The appointment will help uBiome continue its advancement in human microbiome research.
“Manipulating the human microbiome to engineer therapeutics is an exciting frontier and will have huge implications for human health and disease,” Dr. Jessica Richman, PhD, co-founder and CEO of uBiome, said. “We hope to utilize Dr. Oh’s expertise with her addition to our advisory board.”
Dr. Oh is an Assistant Professor of Microbiology at JAX, an independent, nonprofit biomedical research institution which studies genomic solutions to human disease, and Associate Director of the JAX myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) project. In her own lab within JAX, Dr. Oh utilizes genomics, synthetic biology, and genome engineering to manipulate the microbiota for therapeutic purposes. Prior to this role, she was a postdoctoral fellow at the National Human Genome Research Institute of the National Institutes of Health and worked with Dr. Ronald Davis at Stanford on fungal chemogenomics. Dr. Oh received the New Innovator Award from the National Institutes of Health to explore the development of engineered probiotic treatments for a variety of skin and infectious diseases.
About joining uBiome's Scientific Advisory Board, Dr. Oh said, “I’ve followed uBiome’s trajectory over the years, and have been delighted to see their efforts in democratizing microbiome science and more recently, their leadership in driving the adoption of microbiome-based diagnostics in the clinic. I’m very pleased to be able to contribute to their progress in the skin microbiome.”
In addition to Dr. Oh, the uBiome Scientific Advisory Board also includes Dr. Joseph DeRisi (MacArthur Genius and UCSF professor), Dr. Atul Butte (head of the Institute for Computational Health Sciences at UCSF), Dr. Katherine Pollard (Director, Gladstone Institute for Data Science and Biotechnology), Dr. Joel Palefsky (UCSF School of Medicine professor), Dr. George Church (leading geneticist at Harvard University), Dr. Liz Lipski (Academic Director of Nutrition and Integrative Health Programs at Maryland University of Integrative Health), Dr. Elaine Hsiao, PhD (UCLA), and other leading scientists. The company’s Medical Advisory Board includes Dr. Alan Green (Society for Participatory Medicine), Dr. Leo Treyzon (Cedars-Sinai Medical Center), Dr. Cynthia Geyer (Medical Director of Canyon Ranch, Lenox), Dr. Robynne Chutkan (Georgetown University Hospital), Michael Docktor (Boston Children’s Hospital), Dr. Tiffany Lester (Medical Director of Parsley Health in San Francisco), Dr. Joel Kahn (Founder of the Kahn Center for Cardiac Longevity), as well as other accomplished clinicians.
Founded in 2012, uBiome is the leader in microbial genomics. The Company’s mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets. uBiome has filed for over 250 patents on its technology, which includes sample preparation, computational analysis, molecular techniques, as well as diagnostic and therapeutic applications.
uBiome’s commercial products include SmartGut™, the world’s first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn’s Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women’s health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.
uBiome’s platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.
Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company’s Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.